Investor Type | Firm |
Industries | Software (Web Marketplace Saas..) • IT (& TMT) • BioTech • Hardware (& Manufacturing) • HealthTech (& Fitness) • Cloud Services (& Infrastructure) • Material Science • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Life Science • Consumer |
Stages | Seed, Series B, Series A |
Investing | United States |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Assets Under Management | $280,000,000 |
Aisling Capital is a venture capital and private equity firm that focuses on investments in the healthcare and life sciences sectors. Since its inception in 2000, Aisling Capital has been targeting companies that operate within products, technology, global business, and life sciences domains. They position themselves as a key player in funding companies that have the potential to lead and transform the industry. With an emphasis on Software, IT & TMT, Biotech, Hardware & Manufacturing, HealthTech & Fitness, Cloud Services & Infrastructure, Material Science, Medical Devices & Hospital Services, Healthcare & Wellness, Life Science, and Consumer sectors, they provide the necessary capital and support for growth and innovation. Aisling Capital operates with a minimum investment threshold of $100,000 and can invest up to $5,000,000, with a sweet spot at approximately $1,500,000 for investments. Their investment strategy is not confined to a single phase of a company's development; instead, they are known for their versatility in investment stages, which includes Seed, Series A, and Series B rounds. The firm manages assets totaling $280,000,000, leveraging this substantial capital base to foster the next generation of groundbreaking companies at various growth stages. Aisling Capital's aim is to partner with companies to advance scientific and technological innovation, which they believe is key to improving patient outcomes and delivering valuable healthcare solutions.